Zobrazeno 1 - 10
of 130
pro vyhledávání: '"Maria G. Isaguliants"'
Publikováno v:
Cancers, Vol 16, Iss 4, p 818 (2024)
Infections are responsible for approximately one out of six cases of cancer worldwide [...]
Externí odkaz:
https://doaj.org/article/f6ec775679884af59be91aff225ab3ea
Publikováno v:
Infectious Agents and Cancer, Vol 17, Iss S2, Pp 1-19 (2022)
Abstract This is a report on the research activities currently ongoing in virology, oncology and virus-associated cancers and possibilities of their treatment and prevention by vaccines and immunotherapies as outlined at the symposium “Chronic vira
Externí odkaz:
https://doaj.org/article/afb5dcc96ee24d30abdc64f44718abe6
Autor:
Sona Chowdhury, Teresa M. Darragh, J. Michael Berry-Lawhorn, Maria G. Isaguliants, Maxim S. Vonsky, Joan F. Hilton, Ann A. Lazar, Joel M. Palefsky
Publikováno v:
Cancers, Vol 15, Iss 3, p 660 (2023)
The incidence of anal cancer is increasing, especially in high-risk groups, such as PLWH. HPV 16, a high-risk (HR) HPV genotype, is the most common genotype in anal high-grade squamous intraepithelial lesions (HSIL) and squamous cell carcinoma (SCC)
Externí odkaz:
https://doaj.org/article/53777404e51d4aeab256486c6f3c5f09
Autor:
Maria Lina Tornesello, Andrea Cerasuolo, Noemy Starita, Anna Lucia Tornesello, Patrizia Bonelli, Franca Maria Tuccillo, Luigi Buonaguro, Maria G. Isaguliants, Franco M. Buonaguro
Publikováno v:
Cancers, Vol 14, Iss 21, p 5257 (2022)
Human oncoviruses are able to subvert telomerase function in cancer cells through multiple strategies. The activity of the catalytic subunit of telomerase (TERT) is universally enhanced in virus-related cancers. Viral oncoproteins, such as high-risk
Externí odkaz:
https://doaj.org/article/ea46d4d9ebbb4c7aa55e126deef0039f
Autor:
Karen K. Kyuregyan, Vera S. Kichatova, Olga V. Isaeva, Ilya A. Potemkin, Elena Yu. Malinnikova, Maria A. Lopatukhina, Anastasia A. Karlsen, Fedor A. Asadi Mobarhan, Eugeniy V. Mullin, Olga S. Slukinova, Margarita E. Ignateva, Snezhana S. Sleptsova, Elena E. Oglezneva, Elena V. Shibrik, Maria G. Isaguliants, Mikhail I. Mikhailov
Publikováno v:
Vaccines, Vol 9, Iss 2, p 82 (2021)
Universal hepatitis B vaccination of newborns was implemented in Russia starting from 1998. From 1998 to 2019, the incidence of acute hepatitis B reduced from 43.8 to 0.57 cases per 100,000 population. Here, we assessed the timely coverage of newborn
Externí odkaz:
https://doaj.org/article/d808c294bcde458ea2f3b4e8aa4360ca
Autor:
Karlsen Aa, Anna Lyashenko, Alexey Chumakov, Aydar Ishmukhametov, O. V. Isaeva, Alla Kondrashova, Maria G. Isaguliants, Ekaterina Bayurova, K. K. Kyuregyan, I A Potemkin, Mikhail Mikhailov, A. V. Belyakova, Igor Morozov, S. A. Gulyaev, T. I. Gulyaeva, Ilya Gordeychuk, Alexey V. Sorokin
Publikováno v:
Vaccine. 40:89-99
Background Hepatitis E virus (HEV) is a major causative agent of acute hepatitis worldwide, prompting continuous HEV vaccine efforts. Vaccine development is hampered by the lack of convenient animal models susceptible to infection with different HEV
Autor:
Karen K. Kyuregyan, Vera S. Kichatova, Anastasiya A. Karlsen, Olga V. Isaeva, Sergei A. Solonin, Stefan Petkov, Morten Nielsen, Maria G. Isaguliants, Mikhail I. Mikhailov
Publikováno v:
Biomedicines, Vol 8, Iss 4, p 80 (2020)
Direct-acting antivirals (DAAs) revolutionized treatment of hepatitis C virus (HCV) infection. Resistance-associated substitutions (RASs) present at the baseline impair response to DAA due to rapid selection of resistant HCV strains. NS5A is indispen
Externí odkaz:
https://doaj.org/article/e8ec013af29044aa827117b1c2ea6605
Autor:
Alexander V. Ivanov, Olga A. Smirnova, Irina Y. Petrushanko, Olga N. Ivanova, Inna L. Karpenko, Ekaterina Alekseeva, Irina Sominskaya, Alexander A. Makarov, Birke Bartosch, Sergey N. Kochetkov, Maria G. Isaguliants
Publikováno v:
Viruses, Vol 7, Iss 6, Pp 2745-2770 (2015)
Hepatitis C virus (HCV) infection is accompanied by the induction of oxidative stress, mediated by several virus proteins, the most prominent being the nucleocapsid protein (HCV core). Here, using the truncated forms of HCV core, we have delineated s
Externí odkaz:
https://doaj.org/article/8625650ee83e463e9f376a1ba77f5bb8
Autor:
Juris Jansons, Irina Sominskaya, Natalia Petrakova, Elizaveta S. Starodubova, Olga A. Smirnova, Ekaterina Alekseeva, Ruta Bruvere, Olesja Eliseeva, Dace Skrastina, Elena Kashuba, Marija Mihailova, Sergey N. Kochetkov, Alexander V. Ivanov, Maria G. Isaguliants
Publikováno v:
Cells, Vol 8, Iss 3, p 208 (2019)
HCV core is an attractive HCV vaccine target, however, clinical or preclinical trials of core-based vaccines showed little success. We aimed to delineate what restricts its immunogenicity and improve immunogenic performance in mice. We designed plasm
Externí odkaz:
https://doaj.org/article/17bde8c3e2fd48d69f7ffa6d982df1aa
Autor:
Sergey N. Kochetkov, Olga A. Smirnova, Alexander V. Ivanov, Maria G. Isaguliants, Birke Bartosch
Publikováno v:
Viruses, Vol 5, Iss 2, Pp 439-469 (2013)
Hepatitis C virus (HCV) is the etiological agent accounting for chronic liver disease in approximately 2–3% of the population worldwide. HCV infection often leads to liver fibrosis and cirrhosis, various metabolic alterations including steatosis, i
Externí odkaz:
https://doaj.org/article/afe80481ae9947718fbdd0becfb51aa0